PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91025C00018SBIR concept AWARD for a NOVEL — Pathcision Medicine, Inc

Pathcision Medicine, Inc holds $300K across 1 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 55 offers. Set-aside status: SBA. Recompete timing centers on the Feb 10, 2027 PoP end — agencies typically plan 12–18 months ahead.

Nih Nci

Awarding office

Pathcision Medicine, Inc

Recipient

Feb 10, 2027

PoP end

$300K

Obligated

$355K

Potential

541714

NAICS

AN12

PSC

SBA

Set-aside

55 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Pathcision Medicine, Inc — $90

Contract facts

SBA

Contract number75N91025C00018

AgencyNih Nci

Awarding officeNih Nci

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentPathcision Medicine, Inc

CAGE9BD69

UEICK6QRF2GLBT1

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12

Place of performanceWATERTOWN MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

Related solicitation75N91024R00013

PoP startAug 11, 2025

PoP end (current)Feb 10, 2027

Obligated$300K

Current value$355K

Potential value$355K

SBIR CONCEPT AWARD FOR A NOVEL DELIVERY APPROACH TO TRANSFORM METASTATIC PANCREATIC CANCER TREATMENT AND PREVENTION is a federal SBA award for Nih Nci held by Pathcision Medicine, Inc. Estimated value $355K ($300K obligated). Current period of performance ends Feb 10, 2027. Last award drew 55 bidders. Place of performance: WATERTOWN MA. Related solicitation 75N91024R00013.

SBIR CONCEPT AWARD FOR A NOVEL DELIVERY APPROACH TO TRANSFORM METASTATIC PANCREATIC CANCER TREATMENT AND PREVENTION

Recompete timing

Public

● Expiring in 156 days

Current PoP ends Feb 10, 2027 (156 days remaining). Agencies typically plan 12–18 months ahead — at 5.1 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Pathcision Medicine, Inc — $300K obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$300K · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N91025C00018?

75N91025C00018 (SBIR concept AWARD for a NOVEL) is a Nih Nci award with a potential value of $355K, currently held by Pathcision Medicine, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91025C00018?

Nih Nci awarded 75N91025C00018 to Pathcision Medicine, Inc (potential $355K).

Who is the incumbent on 75N91025C00018?

Pathcision Medicine, Inc is the incumbent with $300K across 1 related awards in SCOUT’s public footprint. The current period of performance ends Feb 10, 2027.

When does Pathcision Medicine, Inc’s 75N91025C00018 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 10, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N91025C00018 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jul 20, 2026